INT J CANCER 润色咨询

INTERNATIONAL JOURNAL OF CANCER

出版年份:暂无数据 年文章数:9003 投稿命中率: 开通期刊会员,数据随心看

出版周期:Semimonthly 自引率:2.5% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向:leukemia;biomarker<br>经验分享:请问under evaluation这种状态,一般要多久呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190810, encodeId=4a4511908108b, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:胶质瘤<br>经验分享:我2022.1.23投稿,到现在状态还是under evaluation,已经15天了,要拒怎么不早点拒,还有希望送审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=ms4000001980332372, createdTime=Mon Feb 07 19:27:06 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗?细胞STR鉴定是必须的吗?如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228504, encodeId=5cc61228504f0, content=这个杂志一审拒稿率怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4d25718655, createdName=ms5000000627337742, createdTime=Fri Jun 24 21:14:28 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;临床<br>经验分享:2021年12月13日提交;<br>2022年2月11日 大修;<br> 3月14日修回;<br> 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588956, encodeId=dfdc588956b5, content=据说超过一周就有可能是送审了,我的已经回来了,一审一个月左右<span class="quote">cxw1008 2020-04-14 发表::<br>under review是送审的意思吗?你的结果有回来吗?</span><span class="quote">cxw1008 2020-04-14 00:00:00 发表:<br>under review是送审的意思吗?你的结果有回来吗?</span>, beContent=cxw1008 2020-04-14 发表:: under review是送审的意思吗?你的结果有回来吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fbab2010476, createdName=兮牧歌, createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:分享一下我的投稿经历<br>2020.5.9 submitted to the journal<br>2020.5.11 under evaluation<br>2020.5.11 under review<br>2020.6.7 Awaiting descision<br>2020.6.11 Major revision<br>2020.8.10 Revision submitted<br>2020.8.10 under evaluation<br>2020.8.13 under review<br>2020.9.5 Awaiting descision<br>2020.9.9 Accepted<br>首次投IJC,投的综述,他们的综述一般是约稿,但是也收散稿,我是提前和编辑部发了邮件自荐的,杂志主编看了后很感兴趣,希望我投稿。审稿人虽然是匿名,但是从comments的言辞之间,让我感觉是其中的一位业界大牛Angelika Amon (Koch Institute MIT)。读了她的意见真是醍醐灌顶,受益良多。所以大修之后基本上改的面目全非,但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬,为什么我收不到密码重置的邮件呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向:Meta;epidemiology;Cancer<br>经验分享:International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审,只有一个审稿人审稿,审稿意见比较少,没有实质性的修改意见,这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出,或者工作量不是特别的大,建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]
    2022-08-14 庸医小郝

    审稿速度:1.0 | 投稿命中率:95.0
    经验分享:Under evaluation

    IJC-22-1946
    好几天了

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向:leukemia;biomarker<br>经验分享:请问under evaluation这种状态,一般要多久呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190810, encodeId=4a4511908108b, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:胶质瘤<br>经验分享:我2022.1.23投稿,到现在状态还是under evaluation,已经15天了,要拒怎么不早点拒,还有希望送审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=ms4000001980332372, createdTime=Mon Feb 07 19:27:06 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗?细胞STR鉴定是必须的吗?如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228504, encodeId=5cc61228504f0, content=这个杂志一审拒稿率怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4d25718655, createdName=ms5000000627337742, createdTime=Fri Jun 24 21:14:28 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;临床<br>经验分享:2021年12月13日提交;<br>2022年2月11日 大修;<br> 3月14日修回;<br> 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588956, encodeId=dfdc588956b5, content=据说超过一周就有可能是送审了,我的已经回来了,一审一个月左右<span class="quote">cxw1008 2020-04-14 发表::<br>under review是送审的意思吗?你的结果有回来吗?</span><span class="quote">cxw1008 2020-04-14 00:00:00 发表:<br>under review是送审的意思吗?你的结果有回来吗?</span>, beContent=cxw1008 2020-04-14 发表:: under review是送审的意思吗?你的结果有回来吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fbab2010476, createdName=兮牧歌, createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:分享一下我的投稿经历<br>2020.5.9 submitted to the journal<br>2020.5.11 under evaluation<br>2020.5.11 under review<br>2020.6.7 Awaiting descision<br>2020.6.11 Major revision<br>2020.8.10 Revision submitted<br>2020.8.10 under evaluation<br>2020.8.13 under review<br>2020.9.5 Awaiting descision<br>2020.9.9 Accepted<br>首次投IJC,投的综述,他们的综述一般是约稿,但是也收散稿,我是提前和编辑部发了邮件自荐的,杂志主编看了后很感兴趣,希望我投稿。审稿人虽然是匿名,但是从comments的言辞之间,让我感觉是其中的一位业界大牛Angelika Amon (Koch Institute MIT)。读了她的意见真是醍醐灌顶,受益良多。所以大修之后基本上改的面目全非,但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬,为什么我收不到密码重置的邮件呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向:Meta;epidemiology;Cancer<br>经验分享:International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审,只有一个审稿人审稿,审稿意见比较少,没有实质性的修改意见,这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出,或者工作量不是特别的大,建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]
    2022-08-22 ms5000001852951271

    偏重的研究方向:leukemia;biomarker
    经验分享:请问under evaluation这种状态,一般要多久呢?

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向:leukemia;biomarker<br>经验分享:请问under evaluation这种状态,一般要多久呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190810, encodeId=4a4511908108b, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:胶质瘤<br>经验分享:我2022.1.23投稿,到现在状态还是under evaluation,已经15天了,要拒怎么不早点拒,还有希望送审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=ms4000001980332372, createdTime=Mon Feb 07 19:27:06 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗?细胞STR鉴定是必须的吗?如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228504, encodeId=5cc61228504f0, content=这个杂志一审拒稿率怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4d25718655, createdName=ms5000000627337742, createdTime=Fri Jun 24 21:14:28 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;临床<br>经验分享:2021年12月13日提交;<br>2022年2月11日 大修;<br> 3月14日修回;<br> 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588956, encodeId=dfdc588956b5, content=据说超过一周就有可能是送审了,我的已经回来了,一审一个月左右<span class="quote">cxw1008 2020-04-14 发表::<br>under review是送审的意思吗?你的结果有回来吗?</span><span class="quote">cxw1008 2020-04-14 00:00:00 发表:<br>under review是送审的意思吗?你的结果有回来吗?</span>, beContent=cxw1008 2020-04-14 发表:: under review是送审的意思吗?你的结果有回来吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fbab2010476, createdName=兮牧歌, createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:分享一下我的投稿经历<br>2020.5.9 submitted to the journal<br>2020.5.11 under evaluation<br>2020.5.11 under review<br>2020.6.7 Awaiting descision<br>2020.6.11 Major revision<br>2020.8.10 Revision submitted<br>2020.8.10 under evaluation<br>2020.8.13 under review<br>2020.9.5 Awaiting descision<br>2020.9.9 Accepted<br>首次投IJC,投的综述,他们的综述一般是约稿,但是也收散稿,我是提前和编辑部发了邮件自荐的,杂志主编看了后很感兴趣,希望我投稿。审稿人虽然是匿名,但是从comments的言辞之间,让我感觉是其中的一位业界大牛Angelika Amon (Koch Institute MIT)。读了她的意见真是醍醐灌顶,受益良多。所以大修之后基本上改的面目全非,但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬,为什么我收不到密码重置的邮件呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向:Meta;epidemiology;Cancer<br>经验分享:International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审,只有一个审稿人审稿,审稿意见比较少,没有实质性的修改意见,这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出,或者工作量不是特别的大,建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]
    2022-02-07 ms4000001980332372

    审稿速度:3.0 | 投稿命中率:25.0
    偏重的研究方向:胶质瘤
    经验分享:我2022.1.23投稿,到现在状态还是under evaluation,已经15天了,要拒怎么不早点拒,还有希望送审吗

    4

    展开4条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向:leukemia;biomarker<br>经验分享:请问under evaluation这种状态,一般要多久呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190810, encodeId=4a4511908108b, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:胶质瘤<br>经验分享:我2022.1.23投稿,到现在状态还是under evaluation,已经15天了,要拒怎么不早点拒,还有希望送审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=ms4000001980332372, createdTime=Mon Feb 07 19:27:06 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗?细胞STR鉴定是必须的吗?如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228504, encodeId=5cc61228504f0, content=这个杂志一审拒稿率怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4d25718655, createdName=ms5000000627337742, createdTime=Fri Jun 24 21:14:28 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;临床<br>经验分享:2021年12月13日提交;<br>2022年2月11日 大修;<br> 3月14日修回;<br> 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588956, encodeId=dfdc588956b5, content=据说超过一周就有可能是送审了,我的已经回来了,一审一个月左右<span class="quote">cxw1008 2020-04-14 发表::<br>under review是送审的意思吗?你的结果有回来吗?</span><span class="quote">cxw1008 2020-04-14 00:00:00 发表:<br>under review是送审的意思吗?你的结果有回来吗?</span>, beContent=cxw1008 2020-04-14 发表:: under review是送审的意思吗?你的结果有回来吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fbab2010476, createdName=兮牧歌, createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:分享一下我的投稿经历<br>2020.5.9 submitted to the journal<br>2020.5.11 under evaluation<br>2020.5.11 under review<br>2020.6.7 Awaiting descision<br>2020.6.11 Major revision<br>2020.8.10 Revision submitted<br>2020.8.10 under evaluation<br>2020.8.13 under review<br>2020.9.5 Awaiting descision<br>2020.9.9 Accepted<br>首次投IJC,投的综述,他们的综述一般是约稿,但是也收散稿,我是提前和编辑部发了邮件自荐的,杂志主编看了后很感兴趣,希望我投稿。审稿人虽然是匿名,但是从comments的言辞之间,让我感觉是其中的一位业界大牛Angelika Amon (Koch Institute MIT)。读了她的意见真是醍醐灌顶,受益良多。所以大修之后基本上改的面目全非,但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬,为什么我收不到密码重置的邮件呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向:Meta;epidemiology;Cancer<br>经验分享:International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审,只有一个审稿人审稿,审稿意见比较少,没有实质性的修改意见,这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出,或者工作量不是特别的大,建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]
    2022-02-13 ms5000001945010335

    请问这个杂志要求提供原始数据吗?细胞STR鉴定是必须的吗?如果是那什么时候会要呢

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向:leukemia;biomarker<br>经验分享:请问under evaluation这种状态,一般要多久呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190810, encodeId=4a4511908108b, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:胶质瘤<br>经验分享:我2022.1.23投稿,到现在状态还是under evaluation,已经15天了,要拒怎么不早点拒,还有希望送审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=ms4000001980332372, createdTime=Mon Feb 07 19:27:06 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗?细胞STR鉴定是必须的吗?如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228504, encodeId=5cc61228504f0, content=这个杂志一审拒稿率怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4d25718655, createdName=ms5000000627337742, createdTime=Fri Jun 24 21:14:28 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;临床<br>经验分享:2021年12月13日提交;<br>2022年2月11日 大修;<br> 3月14日修回;<br> 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588956, encodeId=dfdc588956b5, content=据说超过一周就有可能是送审了,我的已经回来了,一审一个月左右<span class="quote">cxw1008 2020-04-14 发表::<br>under review是送审的意思吗?你的结果有回来吗?</span><span class="quote">cxw1008 2020-04-14 00:00:00 发表:<br>under review是送审的意思吗?你的结果有回来吗?</span>, beContent=cxw1008 2020-04-14 发表:: under review是送审的意思吗?你的结果有回来吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fbab2010476, createdName=兮牧歌, createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:分享一下我的投稿经历<br>2020.5.9 submitted to the journal<br>2020.5.11 under evaluation<br>2020.5.11 under review<br>2020.6.7 Awaiting descision<br>2020.6.11 Major revision<br>2020.8.10 Revision submitted<br>2020.8.10 under evaluation<br>2020.8.13 under review<br>2020.9.5 Awaiting descision<br>2020.9.9 Accepted<br>首次投IJC,投的综述,他们的综述一般是约稿,但是也收散稿,我是提前和编辑部发了邮件自荐的,杂志主编看了后很感兴趣,希望我投稿。审稿人虽然是匿名,但是从comments的言辞之间,让我感觉是其中的一位业界大牛Angelika Amon (Koch Institute MIT)。读了她的意见真是醍醐灌顶,受益良多。所以大修之后基本上改的面目全非,但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬,为什么我收不到密码重置的邮件呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向:Meta;epidemiology;Cancer<br>经验分享:International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审,只有一个审稿人审稿,审稿意见比较少,没有实质性的修改意见,这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出,或者工作量不是特别的大,建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]
    2022-06-24 ms5000000627337742

    这个杂志一审拒稿率怎么样

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向:leukemia;biomarker<br>经验分享:请问under evaluation这种状态,一般要多久呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190810, encodeId=4a4511908108b, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:胶质瘤<br>经验分享:我2022.1.23投稿,到现在状态还是under evaluation,已经15天了,要拒怎么不早点拒,还有希望送审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=ms4000001980332372, createdTime=Mon Feb 07 19:27:06 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗?细胞STR鉴定是必须的吗?如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228504, encodeId=5cc61228504f0, content=这个杂志一审拒稿率怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4d25718655, createdName=ms5000000627337742, createdTime=Fri Jun 24 21:14:28 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;临床<br>经验分享:2021年12月13日提交;<br>2022年2月11日 大修;<br> 3月14日修回;<br> 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588956, encodeId=dfdc588956b5, content=据说超过一周就有可能是送审了,我的已经回来了,一审一个月左右<span class="quote">cxw1008 2020-04-14 发表::<br>under review是送审的意思吗?你的结果有回来吗?</span><span class="quote">cxw1008 2020-04-14 00:00:00 发表:<br>under review是送审的意思吗?你的结果有回来吗?</span>, beContent=cxw1008 2020-04-14 发表:: under review是送审的意思吗?你的结果有回来吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fbab2010476, createdName=兮牧歌, createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:分享一下我的投稿经历<br>2020.5.9 submitted to the journal<br>2020.5.11 under evaluation<br>2020.5.11 under review<br>2020.6.7 Awaiting descision<br>2020.6.11 Major revision<br>2020.8.10 Revision submitted<br>2020.8.10 under evaluation<br>2020.8.13 under review<br>2020.9.5 Awaiting descision<br>2020.9.9 Accepted<br>首次投IJC,投的综述,他们的综述一般是约稿,但是也收散稿,我是提前和编辑部发了邮件自荐的,杂志主编看了后很感兴趣,希望我投稿。审稿人虽然是匿名,但是从comments的言辞之间,让我感觉是其中的一位业界大牛Angelika Amon (Koch Institute MIT)。读了她的意见真是醍醐灌顶,受益良多。所以大修之后基本上改的面目全非,但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬,为什么我收不到密码重置的邮件呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向:Meta;epidemiology;Cancer<br>经验分享:International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审,只有一个审稿人审稿,审稿意见比较少,没有实质性的修改意见,这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出,或者工作量不是特别的大,建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]
    2022-04-05 llmmzz0000

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向:肿瘤;临床
    经验分享:2021年12月13日提交;
    2022年2月11日 大修;
    3月14日修回;
    3月29日接收。

    2

    展开2条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向:leukemia;biomarker<br>经验分享:请问under evaluation这种状态,一般要多久呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190810, encodeId=4a4511908108b, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:胶质瘤<br>经验分享:我2022.1.23投稿,到现在状态还是under evaluation,已经15天了,要拒怎么不早点拒,还有希望送审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=ms4000001980332372, createdTime=Mon Feb 07 19:27:06 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗?细胞STR鉴定是必须的吗?如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228504, encodeId=5cc61228504f0, content=这个杂志一审拒稿率怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4d25718655, createdName=ms5000000627337742, createdTime=Fri Jun 24 21:14:28 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;临床<br>经验分享:2021年12月13日提交;<br>2022年2月11日 大修;<br> 3月14日修回;<br> 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588956, encodeId=dfdc588956b5, content=据说超过一周就有可能是送审了,我的已经回来了,一审一个月左右<span class="quote">cxw1008 2020-04-14 发表::<br>under review是送审的意思吗?你的结果有回来吗?</span><span class="quote">cxw1008 2020-04-14 00:00:00 发表:<br>under review是送审的意思吗?你的结果有回来吗?</span>, beContent=cxw1008 2020-04-14 发表:: under review是送审的意思吗?你的结果有回来吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fbab2010476, createdName=兮牧歌, createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:分享一下我的投稿经历<br>2020.5.9 submitted to the journal<br>2020.5.11 under evaluation<br>2020.5.11 under review<br>2020.6.7 Awaiting descision<br>2020.6.11 Major revision<br>2020.8.10 Revision submitted<br>2020.8.10 under evaluation<br>2020.8.13 under review<br>2020.9.5 Awaiting descision<br>2020.9.9 Accepted<br>首次投IJC,投的综述,他们的综述一般是约稿,但是也收散稿,我是提前和编辑部发了邮件自荐的,杂志主编看了后很感兴趣,希望我投稿。审稿人虽然是匿名,但是从comments的言辞之间,让我感觉是其中的一位业界大牛Angelika Amon (Koch Institute MIT)。读了她的意见真是醍醐灌顶,受益良多。所以大修之后基本上改的面目全非,但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬,为什么我收不到密码重置的邮件呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向:Meta;epidemiology;Cancer<br>经验分享:International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审,只有一个审稿人审稿,审稿意见比较少,没有实质性的修改意见,这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出,或者工作量不是特别的大,建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]
    2020-04-15 兮牧歌

    据说超过一周就有可能是送审了,我的已经回来了,一审一个月左右cxw1008 2020-04-14 发表::
    under review是送审的意思吗?你的结果有回来吗?
    cxw1008 2020-04-14 00:00:00 发表:
    under review是送审的意思吗?你的结果有回来吗?

    cxw1008 2020-04-14 发表:: under review是送审的意思吗?你的结果有回来吗?

    7

    展开7条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向:leukemia;biomarker<br>经验分享:请问under evaluation这种状态,一般要多久呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190810, encodeId=4a4511908108b, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:胶质瘤<br>经验分享:我2022.1.23投稿,到现在状态还是under evaluation,已经15天了,要拒怎么不早点拒,还有希望送审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=ms4000001980332372, createdTime=Mon Feb 07 19:27:06 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗?细胞STR鉴定是必须的吗?如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228504, encodeId=5cc61228504f0, content=这个杂志一审拒稿率怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4d25718655, createdName=ms5000000627337742, createdTime=Fri Jun 24 21:14:28 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;临床<br>经验分享:2021年12月13日提交;<br>2022年2月11日 大修;<br> 3月14日修回;<br> 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588956, encodeId=dfdc588956b5, content=据说超过一周就有可能是送审了,我的已经回来了,一审一个月左右<span class="quote">cxw1008 2020-04-14 发表::<br>under review是送审的意思吗?你的结果有回来吗?</span><span class="quote">cxw1008 2020-04-14 00:00:00 发表:<br>under review是送审的意思吗?你的结果有回来吗?</span>, beContent=cxw1008 2020-04-14 发表:: under review是送审的意思吗?你的结果有回来吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fbab2010476, createdName=兮牧歌, createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:分享一下我的投稿经历<br>2020.5.9 submitted to the journal<br>2020.5.11 under evaluation<br>2020.5.11 under review<br>2020.6.7 Awaiting descision<br>2020.6.11 Major revision<br>2020.8.10 Revision submitted<br>2020.8.10 under evaluation<br>2020.8.13 under review<br>2020.9.5 Awaiting descision<br>2020.9.9 Accepted<br>首次投IJC,投的综述,他们的综述一般是约稿,但是也收散稿,我是提前和编辑部发了邮件自荐的,杂志主编看了后很感兴趣,希望我投稿。审稿人虽然是匿名,但是从comments的言辞之间,让我感觉是其中的一位业界大牛Angelika Amon (Koch Institute MIT)。读了她的意见真是醍醐灌顶,受益良多。所以大修之后基本上改的面目全非,但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬,为什么我收不到密码重置的邮件呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向:Meta;epidemiology;Cancer<br>经验分享:International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审,只有一个审稿人审稿,审稿意见比较少,没有实质性的修改意见,这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出,或者工作量不是特别的大,建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]
    2020-09-17 da-xiang

    审稿速度:6.0 | 投稿命中率:25.0
    经验分享:分享一下我的投稿经历
    2020.5.9 submitted to the journal
    2020.5.11 under evaluation
    2020.5.11 under review
    2020.6.7 Awaiting descision
    2020.6.11 Major revision
    2020.8.10 Revision submitted
    2020.8.10 under evaluation
    2020.8.13 under review
    2020.9.5 Awaiting descision
    2020.9.9 Accepted
    首次投IJC,投的综述,他们的综述一般是约稿,但是也收散稿,我是提前和编辑部发了邮件自荐的,杂志主编看了后很感兴趣,希望我投稿。审稿人虽然是匿名,但是从comments的言辞之间,让我感觉是其中的一位业界大牛Angelika Amon (Koch Institute MIT)。读了她的意见真是醍醐灌顶,受益良多。所以大修之后基本上改的面目全非,但是文章的创新型提高好几个层次。

    4

    展开4条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向:leukemia;biomarker<br>经验分享:请问under evaluation这种状态,一般要多久呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190810, encodeId=4a4511908108b, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:胶质瘤<br>经验分享:我2022.1.23投稿,到现在状态还是under evaluation,已经15天了,要拒怎么不早点拒,还有希望送审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=ms4000001980332372, createdTime=Mon Feb 07 19:27:06 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗?细胞STR鉴定是必须的吗?如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228504, encodeId=5cc61228504f0, content=这个杂志一审拒稿率怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4d25718655, createdName=ms5000000627337742, createdTime=Fri Jun 24 21:14:28 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;临床<br>经验分享:2021年12月13日提交;<br>2022年2月11日 大修;<br> 3月14日修回;<br> 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588956, encodeId=dfdc588956b5, content=据说超过一周就有可能是送审了,我的已经回来了,一审一个月左右<span class="quote">cxw1008 2020-04-14 发表::<br>under review是送审的意思吗?你的结果有回来吗?</span><span class="quote">cxw1008 2020-04-14 00:00:00 发表:<br>under review是送审的意思吗?你的结果有回来吗?</span>, beContent=cxw1008 2020-04-14 发表:: under review是送审的意思吗?你的结果有回来吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fbab2010476, createdName=兮牧歌, createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:分享一下我的投稿经历<br>2020.5.9 submitted to the journal<br>2020.5.11 under evaluation<br>2020.5.11 under review<br>2020.6.7 Awaiting descision<br>2020.6.11 Major revision<br>2020.8.10 Revision submitted<br>2020.8.10 under evaluation<br>2020.8.13 under review<br>2020.9.5 Awaiting descision<br>2020.9.9 Accepted<br>首次投IJC,投的综述,他们的综述一般是约稿,但是也收散稿,我是提前和编辑部发了邮件自荐的,杂志主编看了后很感兴趣,希望我投稿。审稿人虽然是匿名,但是从comments的言辞之间,让我感觉是其中的一位业界大牛Angelika Amon (Koch Institute MIT)。读了她的意见真是醍醐灌顶,受益良多。所以大修之后基本上改的面目全非,但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬,为什么我收不到密码重置的邮件呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向:Meta;epidemiology;Cancer<br>经验分享:International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审,只有一个审稿人审稿,审稿意见比较少,没有实质性的修改意见,这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出,或者工作量不是特别的大,建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]
    2021-12-14 ms9482609815413700

    想问下各位大佬,为什么我收不到密码重置的邮件呢?

    2

    展开2条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=1238658, encodeId=36641238658e8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:Under evaluation<br><br>IJC-22-1946<br>好几天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小郝, createdTime=Sun Aug 14 17:48:05 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240341, encodeId=0ebb1240341de, content=偏重的研究方向:leukemia;biomarker<br>经验分享:请问under evaluation这种状态,一般要多久呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Mon Aug 22 20:21:27 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190810, encodeId=4a4511908108b, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:胶质瘤<br>经验分享:我2022.1.23投稿,到现在状态还是under evaluation,已经15天了,要拒怎么不早点拒,还有希望送审吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96255704488, createdName=ms4000001980332372, createdTime=Mon Feb 07 19:27:06 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193008, encodeId=1bad11930087c, content=请问这个杂志要求提供原始数据吗?细胞STR鉴定是必须的吗?如果是那什么时候会要呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c3b5453190, createdName=ms5000001945010335, createdTime=Sun Feb 13 17:05:02 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228504, encodeId=5cc61228504f0, content=这个杂志一审拒稿率怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4d25718655, createdName=ms5000000627337742, createdTime=Fri Jun 24 21:14:28 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208835, encodeId=52ab120883597, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;临床<br>经验分享:2021年12月13日提交;<br>2022年2月11日 大修;<br> 3月14日修回;<br> 3月29日接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00462961920, createdName=llmmzz0000, createdTime=Tue Apr 05 21:10:48 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588956, encodeId=dfdc588956b5, content=据说超过一周就有可能是送审了,我的已经回来了,一审一个月左右<span class="quote">cxw1008 2020-04-14 发表::<br>under review是送审的意思吗?你的结果有回来吗?</span><span class="quote">cxw1008 2020-04-14 00:00:00 发表:<br>under review是送审的意思吗?你的结果有回来吗?</span>, beContent=cxw1008 2020-04-14 发表:: under review是送审的意思吗?你的结果有回来吗?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fbab2010476, createdName=兮牧歌, createdTime=Wed Apr 15 00:00:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:分享一下我的投稿经历<br>2020.5.9 submitted to the journal<br>2020.5.11 under evaluation<br>2020.5.11 under review<br>2020.6.7 Awaiting descision<br>2020.6.11 Major revision<br>2020.8.10 Revision submitted<br>2020.8.10 under evaluation<br>2020.8.13 under review<br>2020.9.5 Awaiting descision<br>2020.9.9 Accepted<br>首次投IJC,投的综述,他们的综述一般是约稿,但是也收散稿,我是提前和编辑部发了邮件自荐的,杂志主编看了后很感兴趣,希望我投稿。审稿人虽然是匿名,但是从comments的言辞之间,让我感觉是其中的一位业界大牛Angelika Amon (Koch Institute MIT)。读了她的意见真是醍醐灌顶,受益良多。所以大修之后基本上改的面目全非,但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079807, encodeId=415e10e98073a, content=想问下各位大佬,为什么我收不到密码重置的邮件呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bvu13d4UOd7Pp29QJYq7ia2iaajBA0KE8iccic6GzEDwjIic2SicpBjc85NgdsmszyXUV1u45c23N5EQWDUdBvJN0gBQ/132, createdBy=cb905406647, createdName=ms9482609815413700, createdTime=Tue Dec 14 08:16:22 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199317, encodeId=b32d119931e55, content=审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3<br>偏重的研究方向:Meta;epidemiology;Cancer<br>经验分享:International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审,只有一个审稿人审稿,审稿意见比较少,没有实质性的修改意见,这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出,或者工作量不是特别的大,建议慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ee2307349, createdName=1221c8e5m44(暂无昵称), createdTime=Fri Mar 04 10:08:38 CST 2022, time=2022-03-04, status=1, ipAttribution=)]
    2022-03-04 1221c8e5m44(暂无昵称)

    审稿速度:3.0 | 投稿命中率:25.0 | 影响因子:7.3
    偏重的研究方向:Meta;epidemiology;Cancer
    经验分享:International Journal Of Cancer 2021.11.19 Submitted 2021.11.22 Under Review 2022.1.3 Under Review 2022.1.11 Under evaluation 2022.1.11 Under Review 2022.1.13 Under evaluation 2022.1.17 Under Review 2022.1.18 Under evaluation 2022.1.19 Under Review 2022.1.31 Under evaluation 2022.1.31 Under Review 2022.2.23 Under evaluation 2022.2.25 Under Review 2022.3.3 Rejected 送了外审,只有一个审稿人审稿,审稿意见比较少,没有实质性的修改意见,这种等了3个月还是会觉得有点不值得。大家如果创新性不是特别突出,或者工作量不是特别的大,建议慎投。

    2

    展开2条回复
共500条页码: 3/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分